Learning Objectives:

After successful completion of this CME/CE activity, learners should be better able to:

 1. Incorporate advances in therapeutic options and understanding of biologics, small molecules, biosimilars, and non-medical therapies for the treatment of Crohn’s disease & ulcerative colitis.

 2. Implement findings of data presented at DDW to improve the care of patients with IBD.

 3. Incorporate quality measures to improve patient health and quality-of-life outcomes.

 

Session date: 
07/02/2024 - 4:30pm to 5:30pm CDT
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please login or create an account to proceed.
Speaker Name: 
David T. Rubin, MD, AGAF